SIGHT-DIAGNOSTICS
Sight Diagnostics Ⓡ , the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, announced today it has raised $71 million in Series D funding with participation from Koch Disruptive Technologies , Longliv Ventures and OurCrowd . This new round brings Sight’s total funding to more than $124 million and will support the expansion of Sight’s commercial operations globally and advance Sight’s R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200805005519/en/
“We firmly believe that Sight’s method of using machine vision to analyze blood is a significant leap forward from the current alternative in healthcare,” said Chase Koch, President of Koch Disruptive Technologies. “Not only is the company bringing truly innovative solutions to the blood diagnostics industry, it is also driving a vision to decentralize information and increase consumer access in healthcare markets across the world.”
Founded in 2011, Sight Diagnostics aims to transform blood testing through its flagship Sight OLOⓇ analyzer which automates the identification and quantification of different blood cell types and anomalies. Sight OLO delivers lab-grade CBC results by measuring 19 different blood parameters in minutes from either a fingerstick or a venous sample. To fuel Sight’s AI-driven method, the company has generated a database of more than half a petabyte of blood imagery, which is used to not only optimize Sight’s current diagnostic algorithms but also to explore new algorithms for the early detection of serious health conditions like sepsis and cancer, as well as blood factors affecting the severity of COVID-19.
“This new investment will enable Sight to substantially expand our U.S. footprint and help usher in a new era of AI-driven diagnostics for a myriad of diseases and health conditions,” said Yossi Pollak, CEO and co-founder of Sight Diagnostics. “We’re glad to have Koch Disruptive Technologies, OurCrowd and other esteemed investors join us on our mission to improve health systems and patient outcomes through developing fast, accurate and less painful diagnostics.”
Since receiving FDA 510(k) clearance* for Sight OLO in late 2019, Sight has continued to expand its global footprint with a specific focus on the US market. Thus far, Sight has secured contractual agreements with healthcare providers and distribution partners to deploy more than 1,000 analyzers over the coming years and will use the funds raised to meet this demand. In parallel, Sight is also working with large pharmaceutical companies, including Pfizer, to provide support for different treatments and therapies. Since early in the pandemic, Sight has deployed its Sight OLO analyzer in frontline healthcare facilities outside of the United States fighting COVID-19, including the globally renowned Sheba Medical Center at Tel Hashomer, Israel.
“At Longliv Ventures, a member of the CK Hutchison Holdings, we look to invest in disruptive companies that aim to dramatically improve lives across the globe,” said Dr. Dan Eldar, the Executive Director of Longliv Ventures. “This is our follow-on investment in Sight Diagnostics, which is now ready to fully commercialize its ground-breaking technology for CBC. We are also excited about the promise of Sight’s computer vision and artificial intelligence capabilities to revolutionize diagnostics in additional areas of hematology and bring about unprecedented rapid and accurate results in a variety of clinical settings”.
“OurCrowd is excited to deepen our relationship with Sight during the company's next phase of growth," said Jon Medved, CEO of OurCrowd. “Sight’s technology has been clinically tested and validated by leading healthcare institutions and we have no doubt it is pioneering the next generation of blood diagnostics."
*In the United States, Sight OLO is 510(k) cleared for use in moderate complexity laboratories; it has not yet been cleared for point-of-care use. Outside of the United States, Sight OLO is CE Marked according to the IVD European directive and approved by the Australian TGA for point of care settings.
About Sight Diagnostics
Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through accurate and pain-free blood diagnostic testing. Sight’s technology, developed over almost a decade of research, represents breakthrough innovations in diagnostic methodology. Sight’s latest blood analyzer, Sight OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes. It’s compact: designed to be used in a variety of settings. Sight OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a finger prick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms. Sight’s first product, Parasight, has been used to detect malaria in almost 1 million tests across 24 countries. The company has rapidly growing offices in the UK, the US and Israel. Learn more at www.SightDX.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005519/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frontline International Names Zack Palazzo Vice President of Sales and Finance26.8.2025 20:14:00 CEST | Press release
Frontline International, a leading maker of smart solutions for management of fats, oils, and grease in restaurants and commercial kitchens, has promoted Zack Palazzo to vice president of sales and finance. Palazzo has been with the company for more than a decade, previously serving as director of sales and finance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826298027/en/ Zack Palazzo, Vice President of Sales and Finance A Purdue University graduate with a degree in industrial technology, he earned his MBA from Kent State University. In his new role, Palazzo will continue to lead sales efforts while taking on increased responsibility for the company’s financial health. He will focus on driving business growth, supporting customers, and developing strategies for long-term success. Palazzo has deep experience overseeing a range of initiatives focused on developing Frontline’s customer base, growing sales, and enhancing
Rigaku Launches Sales of the XHEMIS TX-3000, a TXRF Analytical System for Leading-edge Semiconductor Processes26.8.2025 16:00:00 CEST | Press release
Rigaku’s market dominance in TXRF technology powers up to 6× acceleration in analytical performance Rigaku Corporation, a global solution partner in X-ray analytical systems and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) has launched sales of the XHEMIS (pronounced “ZEM-mis”) TX-3000, a total reflection X-ray fluorescence (TXRF) system that supports analysis of trace contamination on wafer surfaces in semiconductor manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826707850/en/ Measurement result of surface contaminant distribution Rigaku protects the quality with TXRF technology, a field where it holds overwhelming market share Analysis of trace contaminants on wafer surfaces is vital to semiconductor manufacturing. As production steps become increasingly detailed and quality standards grow ever more stringent, this process plays a s
Afton Chemical Launches HiTEC® 65522 Gasoline Performance Additive Series Approved for TOP TIER+™ Gasoline26.8.2025 15:16:00 CEST | Press release
Afton Chemical Corporation, global leader in Gasoline Performance Additives (GPA), is proud to announce the launch of its HiTEC® 65522 GPA series, now approved for use in TOP TIER+™ gasoline. This innovative additive series is designed to meet the evolving needs of modern engine technology, particularly Gasoline Direct Injection (GDI) engines, which are now utilized in 74% of new vehicles in North America, according to the U.S. EPA recent automotive trends report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250819002273/en/ Afton Chemical Headquarters, Richmond, VA USA Twenty years ago, a group of original equipment manufacturers (OEMs) established the voluntary TOP TIER™ standard to enhance fuel detergency and optimize engine performance. Recognizing the advancements in engine technology and the need for updated standards, these OEMs have introduced the revised TOP TIER+™ standard. This new standard includes additional r
MariaDB Accelerates Cloud Deployments, Adds Agentic AI and Serverless Capability with Acquisition of SkySQL26.8.2025 15:00:00 CEST | Press release
Move delivers flexible cloud and hybrid solutions for AI-driven workloads MariaDB plc today announced it has acquired SkySQL Inc., the company behind an AI-powered, serverless database-as-a-service (DBaaS) platform. The acquisition brings SkySQL’s established DBaaS product back into the MariaDB portfolio. SkySQL was originally developed by MariaDB and, since being spun off as an independent entity in 2023, has significantly advanced its product offering. The acquisition of SkySQL enables MariaDB to meet customer and market expectations for greater flexibility and deployment choice, including a range of self-managed and fully managed cloud offerings. MariaDB Cloud will encompass the SkySQL capability and form a key part of the product portfolio. “Our customers have made it clear that they want flexibility, and they need powerful, reliable database solutions wherever their business takes them – on premises, in the cloud or in hybrid environments,” said Rohit de Souza, CEO, MariaDB plc. “
Chicago Atlantic Provides Term Loan to a High Performance Antenna Designer & Manufacturer26.8.2025 15:00:00 CEST | Press release
Chicago Atlantic announced its role as sole arranger and administrative agent in the funding of a senior secured term loan for TrueRC Canada Inc. (“TrueRC”). Founded by Hugo Chamberland in 2014, TrueRC is at the forefront of drone antenna design and manufacturing. “TrueRC’s reputation has been built on delivering high-quality products for both hobbyists and commercial applications alike. From drone racing enthusiasts to professional UAV operators, their antennas have become the trusted standard for performance, durability, and reliability,” said David Enright, Partner & Head of Direct Lending at Chicago Atlantic. “The Company’s commitment to innovation and quality has earned them a loyal global following, and we’re proud to partner with TrueRC as they enter their next phase of growth.” TrueRC specializes in high-performance antennas and related devices for the drone and FPV (First Person View) markets and continues to set the standard for innovation and reliability in the industry. Ope
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom